Differential Regulation of Protein Expression, Growth and Apoptosis by Natural and Synthetic Retinoids

Journal of Cellular Biochemistry

Volumn 90, Issue 4, 2003, Pages 692-708

  Pratt, M A Christine ^a   Niu, Minying ^a   White, Dawn ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

9 cis retinoic acid; All trans retinoic acid; Apoptosis; Cell cycle; Chemosensitization; Protein regulation; Synthetic retinoids

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; ALITRETINOIN; BEXAROTENE; CD 417; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; ESTROGEN RECEPTOR; FENRETINIDE; GENE PRODUCT; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RO 264456; RO 444753; SURVIVIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRAIN ZR 75; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CDC2-CDC28 KINASES; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CLONE CELLS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, RETINOIC ACID; RETINOIDS; S PHASE; TRANSCRIPTION FACTOR AP-1;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0242695616     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10682     Document Type: Article

References (41)

1. Arnold A. 1997. Moving promising research findings to the clinic: Methodological issues in the design and conduct of clinical trials of retinoids. Int J Cancer 70:467-469.
2. Asumendi A, Morales MC, Alaverez J, Pérez-Yarza G. 2002. Implication of mitochondrial-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Br J Cancer 86:1951-1956.
3. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. 2000. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: A role in the control of cyclin D1 expression. EMBO J 19:2056-2068.
4. Benito A, Grillot D, Nunez G, Fernandez-Luna JL. 1995. Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. 146:481-490.
5. Benkoussa M, Brand C, Delmotte MH, Formstecher P, Lefebvre P. 2002. Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter. Mol Cell Biol 22:4522-4534.
6. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA. 1994. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 37:2930-2941.
7. Bollag W, Isnardi L, Jablonska S, Klaus M, Mejewski S, Pirson W, Toma S. 1997. Links between pharmacological properties of retinoids and nuclear retinoid receptors. Int J Cancer 70:470-472.
8. Brand C, Ségard P, Plouvier P, Formstecher P, Danzé PM, Lefebvre P. 2002. Selective alteration of gene expression in response to natural and synthetic retinoids (http://www.biomedcentral.com/1471-2210/2/13).
9. Brichese L, Barboule N, Heliez C, Valette A. 2002. Bcl-2 phosphorylation and proteasome-dependent degradation induced by paclitaxel treatment: Consequences on sensitivity of isolated mitchondria to Bid. Exp Cell Res 278:101-111.
10. Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RK, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R. 1998. Phase I/II trial of all-trans-retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res 4:6635-6642.
11. Caelles C, Gonzalez-Sancho JM, Munoz A. 1997. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 11:3351-3364.
12. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP, Pfahl M. 1994. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107-111.
13. Fanjul AN, Delia D, Pierotti MA, Rideout D, Qui J, Pfahl M. 1996. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271:22441-22446.
14. Grunt THW, Dittrich E, Offterdinger M, Schneider SM, Dittrich CH, Huber H. 1998. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 78:79-87.
15. Guerin E, Ludwig MG, Basset P, Anglard P. 1997. Stromelysin-3 induction and interstitial collagenase repression by retinoic acid. Therapeutical implication of receptor-selective retinoids dissociating transactivation and AP-1 mediated transrepression. J Biol Chem 272:11088-11095.
16. Huang C, Ma W-Y, Dawson MI, Rincon M, Flavell RA, Dong Z. 1997. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 94:5826-5830.
17. Li Y, Hashimoto Y, Agadir A, Kagechika H, Zhang X. 1999. Identification of a novel class of retinoic acid receptor β-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem 22:15360-15366.
18. Lin F, Xiao D, Kolluri SK, Zhang X. 2000. Unique-anti-activator protein-1 activity of retinoic acid receptor beta. Cancer Res 60:3271-3280.
19. Lippman SM, Lotan R, Schleuniger U. 1997. Retinoid-interferon therapy of solid tumors. Int J Cancer 70:481-483.
20. Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC, Zhang X. 1996. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 16:1138-1149.
21. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell 83:841-850.
22. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. 1995. The nuclear receptor superfamily: The second decade. Cell 83:835-839.
23. McBurney MW, Costa S, Pratt MA. 1993. Retinoids and cancer: A basis for differentiation therapy. Cancer Invest 11:590-598.
24. Mouchon A, Delmotte M-H, Formstecher P, Lefebvre P. 1999. Allosteric regulation of the discriminative responsiveness of retinoic acid receptor to natural and synthetic ligands by retinoid X receptor and DNA. Mol Cell Biol 19:3073-3085.
25. Nechushtan A, Smith CL, Hsu YT, Youle RJ. 1999. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 18:2330-2341.
26. Panigone S, Debernardi S, Taya Y, Fontanella E, Airoldi R, Delia D. 2000. pRb and Cdk regulation by N-(4-hydroxyphenyl) retinamide. Oncogene 19:4035-4041.
27. Pfahl M. 1993. Nuclear receptor/AP-1 interaction. Endocr Rev 14:651-658.
28. Poot M, Hosier S, Swisshelm K. 2002. Distinct patterns of mitochondrial changes precede induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl) retinamide in MCF-7 breast cancer cells. Exp Cell Res 279:128-140.
29. Pratt MAC, Niu M-Y. 2003. Bcl-2 controls caspase activation following a p53-dependent cyclin D1-induced death signal. J Biol Chem 278:14219-14229.
30. Pratt MAC, Deonarine D, Teixeira C, Novosad D, Tate BF, Grippo JF. 1996. The AF-2 region of the retinoic acid receptor α mediates retinoic acid inhibition of estrogen receptor function in breast cancer cells. J Biol Chem 271:20346-20352.
31. Raffo P, Emionite L, Colluci L, Belmondo F, Moro MG, Bollag W, Toma S. 2000. Retinoid receptors: Pathways of proliferation inhibition and apoptosis induction in breast cell lines. Anticancer Res 20:1535-1543.
32. Schneider SM, Offterdinger M, Huber H, Grunt TW. 2000. Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells. Cancer Res 60:5479-5487.
33. Seewaldt VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K. 1995. Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest apoptosis in breast cancer cells. Cell Growth Differ 6:1077-1088.
34. Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. 1999. Mediation of N-(4-hydoxyphenyl) Retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59:2493-2498.
35. Suzukawa K, Colburn NH. 2002. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers. Oncogene 21:2181-2190.
36. Teixeira C, Pratt MA. 1997. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol 11:1191-1202.
37. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R, Bollag W. 1997. Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: Growth inhibition and apoptosis induction. Int J Cancer 70:619-627.
38. Um SJ, Lee SY, Kim EJ, Han HS, Koh YM, Hong KJ, Sin HS, Park JS. 2001. Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett 174:127-134.
39. Vivat-Hannah V, You D, Rizzo C, Daris J-P, Lapoointe P, Zusi C, Marinier A, Lorenzi MV, Gottardis MM. 2001. Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with Taxol (Paclitaxel). Cancer Res 61:8703-8711.
40. Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 2000. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 60:2040-2048.
41. Zhou Q, Stetler-Stevenson M, Steeg PS. 1997. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene 15:107-115.